

**Maryland Board of Pharmacy
Public Board Meeting**

**Meeting Minutes
July 18, 2018**

Name		Title	Present	Absent
Ashby, D.	Commissioner			
Bouyoukas, S.	Commissioner			X
Evans, K.	Commissioner			
Gavgani, M.	Commissioner			
Hardesty, J.	Commissioner/Treasurer			X
Laws Jr, A.	Commissioner			X
Leikach, N.	Commissioner			
Morgan, K.	Commissioner/President			
Oliver, B.	Commissioner			
Peters, R.	Commissioner			
Toney, R.	Commissioner/Secretary			
Yankellow, E.	Commissioner			
Bethman, L.	Board Counsel			
Felter, B.	Staff Attorney			
Speights-Napata, D.	Executive Director			
Fields, E.	Deputy Director of Operations			
Logan, B.	Legislation Liaison			X
Brand, E.	Licensing, Legislative and Regulation Manager			
Evans, T.	Compliance Director			
Chew, C.	Management Associate			

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
I. Executive Committee Report(s)	A.) K. Morgan, Board President	<p><i>Members of the Board with a conflict of interest relating to any item on the agenda are advised to notify the Board at this time or when the issue is addressed in the agenda.</i></p> <p>1. Call to Order 9:30 a.m.</p>	1. President K. Morgan provided an update on his attendance and participation in the May, 2018 Hooding Ceremony at UMB and UMES.	
	B.) R. Toney, Secretary	<p>2. Sign-in Introduction and of meeting attendees – <i>(Please indicate on sign-in sheet if you are requesting CE Units for attendance)</i></p> <p>3. Distribution of Agenda and packet materials</p> <p>4. Review and approve June 2018 Public Meeting Minutes</p>	<p>Motion by D. Ashby to approve the June 2018 Public Meeting minutes; 2nd M. Gavgani.</p> <p>.</p>	4. The Board voted to approve this motion.
II. A. Executive Director Report	D. Speights-Napata, Executive Director	<p>1. Operations Updates</p> <p>2. Meetings Update</p> <p>I. Contraception Regulation Meeting Summary</p>	<p>1. Introduction of interns Brad Clark from UMB and Joshua Atere from UMES. Both interns have been assisting with the Contraceptive workgroup.</p> <p>I. The second Contraception meeting was held on July 12th, there were 33 in attendance; including staff. The forms and</p>	

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		II. Draft Tech-Check-Tech Regulations	<p>algorithms are still being discussed for implementation. The minutes for this meeting will be forthcoming. The next Contraception meeting will be held August 30th. The date and time will be posted to the Board's website.</p> <p>II. The Board's internal Tech-Check-Tech workgroup met in June. Commissioner D. Ashby spoke briefly of the origin of the Tech-Check-Tech proposal, and the revisions that were made to the proposal. L. Bethman clarified that this is not a Health Occupation code; this proposal is regulatory revisions, and not a statutory change to the Maryland Pharmacy Act.</p>	
B. Operations Report	E. Fields, Deputy Director/ Operations	<p>1. Administration and Public Support (APS) Unit Updates b) June 2018 Financial Statement</p> <p>2. Management Information Systems (MIS) Unit Updates None</p>	1. A report on Board revenue and expenses through the end of June was provided.	

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results																																			
C. Licensing	E. Brand/ Licensing, Legislative and Regulations Manager	<p>1. Unit Updates</p> <p>2. Monthly Statistics</p> <table border="1"> <thead> <tr> <th>License Type</th><th>New</th><th>Renewed</th><th>Reinstated</th><th>Total</th></tr> </thead> <tbody> <tr> <td>Distributor</td><td>17</td><td>0</td><td>0</td><td>1,272</td></tr> <tr> <td>Pharmacy</td><td>8</td><td>45</td><td>0</td><td>2,089</td></tr> <tr> <td>Pharmacist</td><td>45</td><td>416</td><td>0</td><td>11,700</td></tr> <tr> <td>Vaccination</td><td>21</td><td>6</td><td>0</td><td>4,560</td></tr> <tr> <td>Pharmacy Intern - Graduates</td><td>9</td><td>0</td><td>0</td><td>57</td></tr> <tr> <td>Pharmacy Intern - Students</td><td>53</td><td>19</td><td>0</td><td>958</td></tr> </tbody> </table>	License Type	New	Renewed	Reinstated	Total	Distributor	17	0	0	1,272	Pharmacy	8	45	0	2,089	Pharmacist	45	416	0	11,700	Vaccination	21	6	0	4,560	Pharmacy Intern - Graduates	9	0	0	57	Pharmacy Intern - Students	53	19	0	958		
License Type	New	Renewed	Reinstated	Total																																			
Distributor	17	0	0	1,272																																			
Pharmacy	8	45	0	2,089																																			
Pharmacist	45	416	0	11,700																																			
Vaccination	21	6	0	4,560																																			
Pharmacy Intern - Graduates	9	0	0	57																																			
Pharmacy Intern - Students	53	19	0	958																																			

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results															
		<table border="1"> <tr> <td>Pharmacy Technician</td><td>139</td><td>312</td><td>3</td><td>9,758</td></tr> <tr> <td>Pharmacy Technician Student</td><td>0</td><td>0</td><td>0</td><td>21</td></tr> <tr> <td>TOTAL</td><td>292</td><td>798</td><td>3</td><td>30,415</td></tr> </table>	Pharmacy Technician	139	312	3	9,758	Pharmacy Technician Student	0	0	0	21	TOTAL	292	798	3	30,415		
Pharmacy Technician	139	312	3	9,758															
Pharmacy Technician Student	0	0	0	21															
TOTAL	292	798	3	30,415															
D. Compliance	T. Evans Compliance Director	<p>1. Unit Updates</p> <p>2. Monthly Statistics</p> <p>Complaints & Investigations: New Complaints – 27 Resolved (Including Carryover) –58 Actions within Goal – 27/58 Final disciplinary actions taken – 9 Summary Actions Taken – 2 Average days to complete - 107</p> <p>Inspections: Total – 131 Annual Inspections – 123 Opening Inspections - 4 Closing Inspections – 2 Relocation/Change of Ownership Inspections – 0 Board Special Investigation Inspections – 2</p>																	
E. Legislation & Regulations	E. Brand Licensing, Legislation and Regulations Manager	<u>1. COMAR 10.34.05.05 Security Responsibilities</u>	1. Discussion centered on this regulation needing to define “significant loss”. The amended language will reflect the Federal regulation																

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p data-bbox="583 558 1117 623"><u>2. COMAR 10.34.32.03 D Requirements to Administer Vaccinations</u></p> <p data-bbox="583 824 1192 889"><u>3. COMAR 10.34.40 Pharmacist Prescribing and Dispensing Contraceptives</u></p> <p data-bbox="583 1062 726 1094"><u>Legislation</u></p> <p data-bbox="583 1127 932 1159"><u>2019 Legislative Proposals</u></p> <p data-bbox="592 1198 1045 1230">1. Technician seat on the Board</p>	<p data-bbox="1297 224 1633 386">definition, and the revision of the Division of Drug Control's name to the Office of Controlled Substance and Administration.</p> <p data-bbox="1247 425 1625 522">Motion to approve the amended language by M. Gagvani; 2nd by K. Evans</p> <p data-bbox="1297 561 1625 659">2. This regulation would require the Pharmacist CPR card be readily available.</p> <p data-bbox="1297 828 1617 1094">3. The regulation was published in the Maryland Register on June 22nd, with an effective date of July 2 2018, but pharmacist may not prescribe until January, 2019 when the algorithms are in place.</p> <p data-bbox="1297 1198 1642 1360">1. Following a discussion, a motion was made by M. Gagvani to move to Practice Committee; 2nd by B. Oliver</p>	<p data-bbox="1667 425 2003 490">The Board voted to approve this motion.</p> <p data-bbox="1717 1198 2011 1263">1. The Board voted to approve this motion.</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		2. <u>Generic substitution</u>	2. Motion by E. Yankellow to proceed with the Generic to Brand proposal; 2 nd by K. Evans	2. The Board voted to approve this motion.
III. Committee Reports A. Practice Committee	R. Peters, Chair	<p>1. Question Presented:</p> <p>I am attempting to clarify if it is required by MD law for a pharmacist to provide oversight in the dispensing of oral contrast orders? The Joint Commission makes an exception where pharmacist oversight is not required, but since this is considered a legend medication of federal level I was looking at MD law on this matter.</p> <p>This particular product in question is an oral barium sulfate 2% contrast agent Readicat 2 ndc# 32909-0724-03</p> <p>Proposed Response: Read-Cat 2 NDC# 32909-0723-01 is a prescription drug. The administration and distribution of Read-Cat 2 should follow the hospital policy on administration. The distribution should follow the pharmacy's protocol and procedure for inpatient distribution or the pharmacy's protocol for floor stock distribution in an inpatient setting.</p> <p>2. <u>Protocol for Commissioner Acting on Behalf of the Board</u></p> <p>Committee recommendations:</p> <ol style="list-style-type: none"> 1. Title should be changed from "Commissioner Protocol" to "Commissioner/Staff Protocol" 2. Remove all references to liability in Section C 	<p>1. After a brief discussion motion by M. Gagvani to accept the committees amended response; 2nd by D. Ashby</p> <p>2. Tabled for the August board meeting.</p>	<p>1. The Board voted to approve this motion.</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p>b. KJP-Requests the Board reconsider its denial of the refund for her Pharmacist renewal, as her application was not processed. It was not processed because she did not provide CE's. The Board voted to deny her request at the May 2018 Board meeting. <u>Licensing Committee's Recommendation:</u> Deny</p>	<p>7b. Recommendation by Committee to deny; 2nd by D. Ashby</p>	<p>The Board voted to approve this motion.</p>
<p>C. Public Relations Committee</p>	<p>E. Yankellow, Chair</p>	<p>Public Relations Committee Update:</p> <ul style="list-style-type: none"> • Co-chair, R. Toney presented the Public Relations Committee's recap of the June 27th meeting. She mentioned public outreach of Commissioner N. Leikach attendance at the MPhA conference held June 29th – July 2nd in Ocean City. • Outreach materials are currently being discussed. • The workgroup continues to examine the working conditions throughout Maryland pharmacies. • CE Breakfast will be held October 28th at the Sheraton Baltimore North; the agenda is forthcoming. 		

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
D. Disciplinary	K. Morgan, Chair	Disciplinary Committee Update: <ul style="list-style-type: none"> • A confidential discussion will be held in the Board's Closed Public Session. 		
E. Emergency Preparedness Task Force	N. Leikach, Chair	Emergency Preparedness Task Force Update: NONE		
IV. Other Business & FYI	K. Morgan, President	<ul style="list-style-type: none"> • Executive Director, Aliyah Horton thanked the Board for their presence at the MPhA annual meeting that was held in Ocean City, MD 		
V. Adjournment	K. Morgan, President	A. The Public Meeting was adjourned at 10:40 A.M. B. K. Morgan convened a Closed Public Session to conduct a medical review committee evaluation of confidential applications. C. The Closed Public Session was adjourned. Immediately thereafter, K. Morgan, convened an Administrative Session for purposes of discussing confidential disciplinary cases. D. With the exception of cases requiring recusals, the Board members present at the	Motion to close the Public Board Meeting by D. Ashby; 2 nd by K. Evans.	The Board voted to approve this motion.

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		Public Meeting continued to participate in the Closed Public Session and the Administrative Session.		